Healthcare Equipment and Supplies
Company Overview of Arch Therapeutics, Inc.
Arch Therapeutics, Inc. operates as a life science medical device company. The company focuses on developing products by utilizing a novel approach to stop bleeding and control leaking during surgery and trauma care. Its lead product candidate includes AC5 Surgical Hemostatic Device, a biocompatible synthetic peptide, which comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Wellesley, Massachusetts.
20 William Street
Wellesley, MA 02481
Founded in 2006
Key Executives for Arch Therapeutics, Inc.
Total Annual Compensation: $390.8K
Chief Financial Officer and Treasurer
Total Annual Compensation: $87.2K
Chief Operating Officer
Total Annual Compensation: $253.3K
Total Annual Compensation: $92.0K
Compensation as of Fiscal Year 2014.
Arch Therapeutics, Inc. Key Developments
Arch Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015
Jan 8 15
Arch Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.
Arch Therapeutics, Inc. Announces Positive Results for AC5 Surgical Hemostatic Device in Biochemical and Cell Function Safety Studies
Jan 6 15
Arch Therapeutics, Inc. obtained positive results from preclinical tests in which AC5 was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical 'switches', and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care. In this in vitro study panel, AC5 tested in relevant amounts had no interactions with the examined 71 individual cell receptors or 211 separate cell kinase enzymes. These outcomes support AC5 as a non-toxic product to biochemical targets. Results from these safety interaction studies indicate that AC5's mechanism of action, which is the formation of a local physical-mechanical barrier, does not rely on AC5's interaction with known human receptors or enzymes to inhibit bleeding and leaking.
Arch Therapeutics, Inc. Presents at LD Micro Conference, Dec-04-2014 12:00 PM
Nov 24 14
Arch Therapeutics, Inc. Presents at LD Micro Conference, Dec-04-2014 12:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Terrence W. Norchi, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|